CLINICAL TRIAL: PHASE II TRIAL OF CTLA4IG IN THE TREATMENT OF LUPUS NEPHRITIS

临床试验：CTLA4IG 治疗狼疮性肾炎的 II 期试验

• 批准号: 7951961
• 负责人: MEGGAN MACKAY
• 金额: $ 0.18万
• 依托单位: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951961
• 关键词: Azathioprine; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Cyclophosphamide; Disease remission; Frequencies; Funding; Grant; Immunosuppressive Agents; Institution; Lupus Nephritis; Pharmaceutical Preparations; Phase II Clinical Trials; Protocols documentation; Research; Research Personnel; Resources; Safety; Source; Testing; United States National Institutes of Health; Vaccination; design; partial response; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is designed to test whether addition of Abatacept to a 24-week induction protocol involving cyclophosphamide followed in turn by azathioprine can induce remission with greater frequency than treatment with cyclophosphamide and azathioprine alone. Secondary objectives are to determine the safety of the agent, the durability of the response when the immunosuppressive medications are stopped and the partial response rate. Finally, a third secondary objective is to ascertain whether the Abatacept enables greater response to vaccinations compared to therapy with cyclophosphamide alone.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 该项目旨在测试在涉及环磷酰胺的24周诱导方案中添加AbatacePT是否可以依次诱导硫唑嘌呤，而单独使用环磷酰胺和硫唑嘌呤治疗的频率更高。 次要目标是确定药物的安全性，当免疫抑制药物停止和部分缓解率时，反应的耐用性。 最后，第三个次要目标是确定与单独使用环磷酰胺的治疗相比，Abatacept是否可以对疫苗接种的反应更大。